ZA200801923B - Treatment of optic neuritis - Google Patents

Treatment of optic neuritis

Info

Publication number
ZA200801923B
ZA200801923B ZA200801923A ZA200801923A ZA200801923B ZA 200801923 B ZA200801923 B ZA 200801923B ZA 200801923 A ZA200801923 A ZA 200801923A ZA 200801923 A ZA200801923 A ZA 200801923A ZA 200801923 B ZA200801923 B ZA 200801923B
Authority
ZA
South Africa
Prior art keywords
treatment
optic neuritis
neuritis
optic
Prior art date
Application number
ZA200801923A
Other languages
English (en)
Inventor
Sergott Robert
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of ZA200801923B publication Critical patent/ZA200801923B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200801923A 2005-09-01 2006-08-30 Treatment of optic neuritis ZA200801923B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71324605P 2005-09-01 2005-09-01

Publications (1)

Publication Number Publication Date
ZA200801923B true ZA200801923B (en) 2009-09-30

Family

ID=37478847

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801923A ZA200801923B (en) 2005-09-01 2006-08-30 Treatment of optic neuritis

Country Status (12)

Country Link
US (1) US8178083B2 (xx)
EP (1) EP1933860A2 (xx)
JP (1) JP2009507003A (xx)
KR (1) KR20080050591A (xx)
CN (1) CN101282740A (xx)
AU (1) AU2006286489B2 (xx)
BR (1) BRPI0616118A2 (xx)
CA (1) CA2616479A1 (xx)
EA (1) EA013816B1 (xx)
IL (1) IL189849A (xx)
WO (1) WO2007025991A2 (xx)
ZA (1) ZA200801923B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX2014001048A (es) * 2011-07-28 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimo de interferon-beta.
RU2494709C1 (ru) * 2012-05-16 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения острого неврита зрительного нерва

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0070906B1 (en) 1981-02-04 1986-10-15 Juridical Foundation Japanese Foundation For Cancer Research Human interferon-beta gene
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0325224B1 (en) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JP2864434B2 (ja) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0727406B1 (de) 1995-02-16 2001-09-05 MERCK PATENT GmbH Vinylenverbindungen und flüssigkristallines Medium
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CZ96798A3 (cs) * 1997-04-02 1998-10-14 Sankyo Company Limited Deriváty dithiolanu, jejich příprava a jejich terapeutické účinky
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
CZ298597B6 (cs) 1998-04-28 2007-11-21 Applied Research Systems Ars Holding N. V. Zpusob postupné vazby polyethylenglykolových skupin na polypeptid
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
IL142350A0 (en) 1998-10-16 2002-03-10 Biogen Inc Interferon-beta fusion proteins and pharmaceutical compositions containing the same
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6356036B1 (en) * 2000-12-01 2002-03-12 Laser Diagnostic Technologies, Inc. System and method for determining birefringence of anterior segment of a patient's eye
DK1377593T3 (da) 2001-03-26 2006-04-10 Novartis Ag 2-Amino-propanolderivater
CA2443285C (en) 2001-04-05 2007-08-21 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
OA12771A (en) 2002-02-14 2006-07-04 Pharmacia Corp Substituted pyridinones as modulators of P38 map kinase.
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US7016048B2 (en) * 2002-04-09 2006-03-21 The Regents Of The University Of California Phase-resolved functional optical coherence tomography: simultaneous imaging of the stokes vectors, structure, blood flow velocity, standard deviation and birefringence in biological samples
TWI376363B (en) * 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
KR20050048642A (ko) 2002-09-25 2005-05-24 메이지 세이카 가부시키가이샤 서방성 농약 입제
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
EA013816B1 (ru) 2010-08-30
BRPI0616118A2 (pt) 2011-06-07
IL189849A0 (en) 2008-11-03
AU2006286489B2 (en) 2012-08-09
CN101282740A (zh) 2008-10-08
JP2009507003A (ja) 2009-02-19
EP1933860A2 (en) 2008-06-25
CA2616479A1 (en) 2007-03-08
IL189849A (en) 2012-04-30
AU2006286489A1 (en) 2007-03-08
KR20080050591A (ko) 2008-06-09
WO2007025991A3 (en) 2007-05-10
US8178083B2 (en) 2012-05-15
WO2007025991A2 (en) 2007-03-08
EA200800729A1 (ru) 2008-06-30
US20080317711A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
IL188746A0 (en) Treatment of cancer
EP2020970A4 (en) TREATMENT OF THE EYE
EP1982660A4 (en) TREATMENT ENDOSCOPE
IL188430A0 (en) Treatment of tumors
IL190779A0 (en) Compositions for treatment of eye diseases
GB0600692D0 (en) Well treatment
PT2007942E (pt) Tratamento de têxteis num passo
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
PL2056863T3 (pl) Leczenie chorób oczu
GB0605715D0 (en) Treatment of laminitis
GB0516068D0 (en) Well treatment
ZA200806505B (en) Treatment of HIV
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
EP2051651A4 (en) LASER TREATMENT OF TISSUE
GB0607952D0 (en) Novel treatment
ZA200801923B (en) Treatment of optic neuritis
GB0723100D0 (en) Treatment of HFnEF
GB0520067D0 (en) Treatment of cancer
GB0502171D0 (en) Well treatment
GB0623740D0 (en) Treatment of disease
GB0602857D0 (en) The treatment of sialorrhoea
PT2074257T (pt) Tratamento de pasta
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0518003D0 (en) Treatment of hepatatis c
GB0518122D0 (en) Treatment of coccidiosis